|
2.4 Etiologie - Portables, ondes e-m
|
|
|
Rodents and Radiation: What to Take Away from New Study Findings [ACS]
|
|
|
|
|
|
“A
final point to remember is that we should not base our decisions or our
point of view on a single study. When deciding where the truth lies,
you really need to take all the available evidence into account. And in
fact, most studies looking into cell phones and cancer are negative.”
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cellphones Are Still Safe for Humans, Researchers Say [NY Times]
|
|
|
|
|
|
The
rodents in the studies were exposed to radiation nine hours a day for
two years, more than people experience even with a lot of cellphone use,
so the results cannot be applied directly to humans, said John Bucher, a
senior scientist at the National Toxicology Program, during a telephone
news briefing.
|
|
|
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.10 Immunothérapies - Fusions et acquisitions
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
Pharma Investors Suffer From Tax Myopia [Blomberg]
|
|
|
|
|
|
For
now at least, Keytruda is in an exceptionally valuable pole position
that Merck is spending aggressively to maintain; the company said on its
conference call that there are 700 registered clinical trials involving
the drug, 400 of them testing it in combination with other medicines.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.4 Traitements - Economie
|
|
|
Faslodex rejected by NICE for NHS breast cancer use [Pharmafile]
|
|
|
|
|
|
Bad
news for breast cancer patients in the UK as the National Institute for
Health and Care Excellence announces it has decided to reject
AstraZeneca’s Faslodex (fulvestrant) on the basis that it cannot
reconcile its cost-effectiveness for use on the NHS.
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
Breast cancer death rate down 10% in just five years [Cancer Research UK]
|
|
|
|
|
|
Despite
the ‘big four’ cancer types seeing death rates fall by over 5%, the
overall rate is tempered by the hard-to-treat cancer types. Survival
remains stubbornly low in cancers of the pancreas, brain and oesophagus
showing how much research is still needed to lower mortality rates
across the board.
|
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
|
6.8 Communication
|
|
|